This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
本发明涉及新型的3-取代喹诺
啡啶衍
生物,发现它们是
烟碱乙酰胆碱受体的
胆碱能
配体,并且是单胺受体和转运体的调节剂。由于它们的药理特性,本发明的化合物可能用于治疗与中枢神经系统(CNS)和外周神经系统(
PNS)的
胆碱能系统有关的疾病或障碍,与平滑肌收缩有关的疾病或障碍,内分泌疾病或障碍,与神经退行性有关的疾病或障碍,与炎症、疼痛以及由滥用
化学物质终止引起的戒断症状有关的疾病或障碍。